Please assess the completion status of the following clinical trial:

Trial Title: RCT to Compare Orlistat and Polyglucosamine for the Management of Overweight and Obesity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* BMI ≥ 28 kg/m² and \< 45 kg/m²~* Waist circumference \> 80 cm (women) \> 94 cm (men)~Exclusion Criteria:~* Energy intake lower than the standard value according to Miffin St-Jeor equation~* Pregnancy or breast-feeding~* Addiction to alcohol~* Inability to fulfil the requirement of the trial protocol~* Cancer ,malignant tumour~* Hypersensitivity reactions to crustaceans or ingredient of the study medication~* Chronic diseases not under control with adequate therapy~* Diabetes

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Drug: orlistat 60mg capsules (Type: ACTIVE_COMPARATOR): A tailored blister-strip for one day contains~* three capsules with orlistat 60mg Administration: 3 times daily 1 capsule with each meal containing fat concomitant with~* six placebo tablets Administration: 3 times daily 2 tablets with each main meal
- Medical device: polyglucosamine (Type: ACTIVE_COMPARATOR): A tailored blister-strip for one day contains~* three placebo capsules Administration: 3 times daily 1 capsule with each meal containing fat concomitant with~* six tablets Administration: 3 times daily 2 tablets (whereas the 2 tablets in the mold breakfast are placebo tablets and the remaining 4 tablets for lunch and dinner contains poliglucosamine

Based on this trial design, predict the completion outcome and termination type (if applicable).